[{"id":"163ac97d-61c1-4dda-8fa6-429e5d0086da","acronym":"","url":"https://clinicaltrials.gov/study/NCT06762925","created_at":"2025-02-26T07:20:20.648Z","updated_at":"2025-02-26T07:20:20.648Z","phase":"","brief_title":"Study on the Efficacy and Mechanism of METTL3 Peptide Inhibitors in Enhancing Anti-tumor Immune Response by Reshaping the Tumor Microenvironment","source_id_and_acronym":"NCT06762925","lead_sponsor":"Xijing Hospital","biomarkers":" METTL3","pipe":"","alterations":" ","tags":["METTL3"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 450","initiation":"Initiation: 01/30/2025","start_date":" 01/30/2025","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-01-08"},{"id":"ea91aacb-1bbe-443e-8688-510a2808a6b6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05584111","created_at":"2024-01-23T21:20:09.771Z","updated_at":"2024-07-02T16:35:22.479Z","phase":"Phase 1","brief_title":"Oral Administration of STC-15 in Subjects With Advanced Malignancies","source_id_and_acronym":"NCT05584111","lead_sponsor":"STORM Therapeutics LTD","biomarkers":" METTL3","pipe":"","alterations":" ","tags":["METTL3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STC-15"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 11/15/2022","start_date":" 11/15/2022","primary_txt":" Primary completion: 05/30/2024","primary_completion_date":" 05/30/2024","study_txt":" Completion: 05/30/2025","study_completion_date":" 05/30/2025","last_update_posted":"2024-01-23"}]